\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital, Industry & SpaceThe project DiMAT, funded by Horizon Europe and focusing on "Digital Modelling and Simulation for Design, Processing and Manufacturing of Advanced Materials" is looking for input.
The project currently gathers industry feedback for the solutions it is developing - open digital tools for SMEs in Materials Manufacturing.
These tools will help companies model, stimulate and optimize materials throughout the value chain.
To collect feedback, the project is conducting a brief, anonymous survey (about 15 minutes) that will help to refine the DiMAT solution's offer for SMEs.
Survey link here: https://docs.google.com/forms/d/e/1FAIpQLSd7LzVpehwgCF8-qH5qwiN343j6eW7zmFWGGIrvOOtjxKKTHw/viewform
Later this year, a call for early adopters will be launched with access to the DiMAT solutions and tailored experts support.
Participating in this survey will give materials manufacturing SMEs located in Flanders the opportunity to provide their input on their needs to allow the project to tailor its offers for SMEs.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
